Marc de Garidel is CEO at CinCor Pharma, Inc. (CINC). They have made 1 open-market trade across 1 company since 2022, most recently 2023-02-24.
CIK 0001901033
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $200K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CINC | 212,500 | $6.2M |
Shares reported on the most recent Form 4, priced at the 2023-01-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CINC | BUY | 2022-01-11 | 2022-01-13 | $16.00 | $200K | +6.3% | +41.7% | +28.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.